Afuco™ Anti-RSPO3 ADCC Therapeutic Antibody (Rosmantuzumab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to RSPO3. Rosmantuzumab is a humanized monoclonal antibody that can be potentially used in the treatment of Advanced Relapsed Tumor, Refractory Solid Tumors.
Supplier Creative Biolabs
Product # AFC-TAB-449CQ
Pricing Inquiry
Host Human
Target RSPO3
Species Reactivity Human
Type ADCC enhanced antibody
Applications ELISA, IHC, FC, IP, IF, FuncS
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback